Optiquel: Phase I/II started

Enzo began a double-blind, placebo-controlled, U.S. Phase I/II trial to evaluate thrice-weekly 1 and 4 mg oral Optiquel for 24 weeks in about 60 patients. Optiquel has Orphan Drug designation in the E...